Wednesday, June 12, 2019

MissionIRNewsBreaks – Pressure BioSciences Inc.’s (PBIO) PCT Platform Prominently Featured in Record Number of ASMS Presentations


Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of high pressure-based instruments, consumables, and related services for the global life sciences and other industries worldwide, today announced its patented pressure cycling technology (“PCT”) platform was prominently featured in 15 independent presentations at the annual conference of the American Society for Mass Spectrometry (“ASMS”). The presentations at the ASMS conference, held from June 1-6, 2019 in Atlanta, Georgia, spanned PBI’s unique PCT platform’s wide ranging applications in scientific studies, particularly in advancing knowledge and understanding in such areas as cancer research, protein function, molecular biology, and biomarker discovery. “The number of PCT-related presentations at the 2019 ASMS conference significantly exceeded prior PBI records for a scientific meeting,” PBI’s Global Director of Sales & Marketing Roxana McCloskey said in the news release. “We are gratified that the use of our PCT platform continues to expand to new investigators and laboratories worldwide, and that its use has shown great promise in critical areas of human health, such as cancer. We believe the presentations at this prestigious annual meeting clearly show the increasing potential for the PCT platform in diagnostics and discovery, which we believe could eventually lead to the routine use of the PCT platform in precision medicine, a rapidly expanding market that is expected to reach $217 billion by 2028 (BIS Research, 2019).”

To view the full press release, visit http://ibn.fm/lAIfU

About Pressure BioSciences Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html